IP Library › Assignment 072881/0270

Patent Assignment

Reel/Frame 072881/0270

Assignee Change of Address

Recorded: 2025-09-16 Pages: 23

View PDF Order Certified Copy

Assignor

PRINCIPIA BIOPHARMA INC.

Executed: 2025-09-16

Assignee

PRINCIPIA BIOPHARMA INC.

100 MORRIS STREET, MORRISTOWN, NEW JERSEY, 07960

Covered Properties (228)

Tyrosine Kinase Inhibitors

Application: 62/271,689 →

Tyrosine Kinase Inhibitors

Application: 62/170,547 →

Tyrosine Kinase Inhibitors

Application: 18/960,997 →

Publication: US 2025/0197402

Tyrosine Kinase Inhibitors

Application: 17/974,613 →

Publication: US 2023/0151012

Tyrosine Kinase Inhibitors

Application: 17/029,184 →

Publication: US 2021/0171526

Tyrosine Kinase Inhibitors

Application: 15/578,623 →

Publication: US 2018/0162861

Tyrosine Kinase Inhibitors

Patent: 9,688,676 →

Application: 15/410,716 →

Publication: US 2017/0129890

Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (Rms)

Application: 63/013,895 →

Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (Rms)

Application: 62/970,502 →

Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (Rms)

Application: 62/963,238 →

Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)

Patent: 12,636,280 →

Application: 18/613,641 →

Publication: US 2024/0366585

4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2H-Imidazo[4,5-C]Pyridin-2-One Derivatives and Salts Thereof

Application: 63/245,288 →

4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2H-Imidazo[4,5-C]Pyridin-2-One Derivatives and Salts Thereof

Application: 63/130,010 →

4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2H-Imidazo[4,5-C]Pyridin-2-One Derivatives and Salts Thereof

Patent: 12,624,030 →

Application: 18/268,577 →

Publication: US 2024/0051955

Tyrosine Kinase Inhibitors

Application: 61/618,152 →

Tyrosine Kinase Inhibitors

Application: 61/556,336 →

Tyrosine Kinase Inhibitors

Application: 61/514,892 →

Tyrosine Kinase Inhibitors

Application: 61/486,944 →

Tyrosine Kinase Inhibitors

Application: 14/590,851 →

Publication: US 2015/0353557

Formulations Containing Reversible Covalent Compounds

Application: 61/661,203 →

Formulations Containing Reversible Covalent Compounds

Application: 14/403,744 →

Publication: US 2016/0045503

Pyrazolopyrimidine Compounds as Kinase Inhibitors

Application: 61/782,605 →

Pyrazolopyrimidine Compounds as Kinase Inhibitors

Application: 61/728,693 →

Tyrosine Kinase Inhibitors

Application: 61/699,038 →

Pyrazolopyrimidine Compounds As Kinase Inhibitors

Application: 19/259,297 →

Pyrazolopyrimidine compounds as kinase Inhibitors

Application: 18/344,167 →

Publication: US 2024/0174676

Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors

Application: 17/324,674 →

Publication: US 2022/0073522

Azaindole Derivatives as JAK3 Inhibitors

Application: 61/728,539 →

Salts and Solid Form of a Btk Inhibitor

Application: 62/096,468 →

Salts and Solid Form of a Btk Inhibitor

Application: 61/946,480 →

Salts and Solid Form of a Btk Inhibitor

Application: 61/943,262 →

Salts and Solid Form of a BTK Inhibitor

Application: 17/752,012 →

Publication: US 2022/0370459

Compositions for Ileo-Jejunal Drug Delivery

Application: 62/096,812 →

Compositions for Ileo-Jejunal Drug Delivery

Application: 15/539,100 →

Publication: US 2018/0193274

Treatment of Pemphigus

Application: 62/093,891 →

Site Specific Administration of a Btk Inhibitor

Application: 62/096,809 →

Site Specific Dosing of a Btk Inhibitor

Application: 15/539,094 →

Publication: US 2018/0015088

Tyrosine Kinase Inhibitors

Application: 62/271,715 →

Tyrosine Kinase Inhibitors

Application: 62/183,969 →

Tyrosine Kinase Inhibitors

Application: 15/738,051 →

Publication: US 2018/0305350

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 62/356,345 →

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-Enenitrile

Application: 19/217,161 →

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 16/312,258 →

Publication: US 2019/0231784

Method of Treating Pemphigus by Administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Application: 62/942,877 →

Application: 62/913,029 →

Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

Application: 17/957,073 →

Publication: US 2023/0158033

Methods of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 17/066,300 →

Publication: US 2021/0106583

Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 62/951,302 →

Application: 62/914,688 →

Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

Application: 18/950,981 →

Publication: US 2025/0221999

Application: 17/069,218 →

Publication: US 2021/0106584

Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/122,309 →

Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 62/951,958 →

PROCESS FOR PREPARING AN AMORPHOUS FORM OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXYPHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

Application: 18/197,979 →

Publication: US 2023/0399330

TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONY]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERIZIN-1-YL]PENT-2-ENENITRILE

Application: 63/039,200 →

Application: 62/957,724 →

TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

Application: 17/141,930 →

Publication: US 2021/0205312

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Application: 62/958,389 →

Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Application: 63/003,536 →

Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Application: 62/958,616 →

Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Application: 18/889,671 →

Publication: US 2025/0099470

Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Application: 18/153,528 →

Publication: US 2023/0277542

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Peperazin-1-Yl]Pent-2-Enenitrile

Application: 62/964,378 →

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- Enenitrile

Application: 19/208,781 →

Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using Btk Inhibitors

Application: 63/013,784 →

Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors

Application: 17/920,147 →

Publication: US 2023/0158031

Methods for Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds

Application: 63/175,976 →

Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds

Application: 18/555,388 →

Publication: US 2024/0207277

Immunoproteasome Inhibitors

Application: 62/508,771 →

Immunoproteasome Inhibitors

Application: 62/447,717 →

Immunoproteasome Inhibitors

Application: 62/587,375 →

Immunoproteasome Inhibitors

Application: 62/587,376 →

Benzimidazole Derivatives as ITK Inhibitors

Application: 61/782,213 →

Benzimidazole Derivatives as Itk Inhibitors

Application: 61/728,670 →

Benzimidazole Derivatives as Kinase Inhibitors

Application: 61/695,673 →

Quinolone Derivatives as Fibroblast Growth Factor Inhibitors

Application: 61/821,468 →

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Application: 62/069,932 →

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Application: 62/007,562 →

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Application: 61/937,211 →

Quinolone Derivatives as Fibroblast Growth Factor Inhibitors

Application: 17/306,528 →

Publication: US 2021/0292323

Quinolone Derivatives as Fgfr Inhibitors

Application: 62/165,526 →

Processes for Preparing an Fgfr Inhibitor

Application: 62/203,498 →

Process for Preparing an FGFR Inhibitor

Application: 18/672,343 →

Publication: US 2024/0309000

Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and Derivatives Thereof

Application: 63/432,169 →

Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and Derivatives Thereof

Application: 63/292,124 →

Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof

Application: 18/722,486 →

Publication: US 2025/0145618

Cyclic Boronic Esters and Their Uses

Application: 63/357,093 →

Cyclic Boronic Esters and Their Uses

Application: 18/876,345 →

Tyrosine Kinase Inhibitors

Application: 14/741,311 →

Publication: US 2015/0353562

Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/352,027 →

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 18/874,401 →

Therapeutic Tyrosine Kinase Inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Disease (Mogad)

Application: 63/433,853 →

Therapeutic Tyrosine Kinase Inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Disease (Mogad)

Application: 63/341,486 →

Therapeutic Tyrosine Kinase Inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Disease (Mogad)

Application: 18/864,343 →

Methods of Making Tolebrutinib

Application: 63/351,996 →

Methods of Making Tolebrutinib

Application: 18/976,520 →

Publication: US 2025/0101021

Methods of Making Modified Btk Inhibitors

Application: 63/354,330 →

Process of Making 2-[(3R)-2-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4[4-(Oxetan-3-Yl)Piperazin-1-Yl]-Pent-2-Enenitrile and Solvate Forms Thereof

Application: 18/789,827 →

Publication: US 2025/0084085

Application: 63/530,142 →

Drug Formulations of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One

Application: 63/433,824 →

Drug Formulations of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One

Application: 18/545,029 →

Publication: US 2024/0238267

Methods for Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enentrile

Application: 63/386,094 →

Application: 63/420,864 →

Application: 19/194,148 →

Publication: US 2025/0255874

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis and Myasthenia Gravis

Application: 63/433,866 →

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis and Myasthenia Gravis

Application: 63/357,465 →

Therapeutic Tyrosine Kinase Inhibitors For Multiple Sclerosis and Myasthenia Gravis

Application: 18/987,395 →

Publication: US 2025/0262193

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis

Application: 63/433,873 →

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis

Application: 63/415,027 →

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis

Application: 18/377,540 →

Publication: US 2024/0173313

Methods for Treating Immune Thrombocytopenia in Subjects with Cognitive Impairment by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/605,721 →

Application: 63/386,710 →

Methods for Treating Immune Thrombocytopenia in Subjects with Cognitive Impairment by Administering Rilzabrutinib

Application: 19/160,970 →

Treatment of Itch Associated with Atopic Dermatitis and/or Prurigo Nodularis using BTK Inhibitor 2-[(3R)-3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-d]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/697,819 →

TREATMENT OF ITCH ASSOCIATED WITH ATOPIC DERMATITIS AND/OR PRURIGO NODULARIS USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

Application: 63/606,912 →

Treatment of Itch Associated with Atopic Dermatitis Using Btk Inhibitor 2-[(3R)-3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/593,108 →

Methods of Diagnosing and Treating Multiple Sclerosis

Application: 63/623,681 →

Methods of Diagnosing and Treating Multiple Sclerosis

Application: 63/482,714 →

Methods of Diagnosing and Treating Multiple Sclerosis by Detecting a Biomarker in the Cerebrospinal Fluid

Application: 19/285,681 →

Publication: US 2025/0354998

Methods for Treating Persistent or Chronic Immune Thrombocytopenia in Children, Adolescents and Adults by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazoleo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)PiperazinN-1-YL]Pent-2-Enenitrile

Application: 63/637,286 →

Methods for Treating Persistent or Chronic Immune Thrombocytopenia in Children, Adolescents and Adults by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/607,818 →

Methods for Treating Persistent or Chronic Immune Thrombocytopenia in Children, Adolescents and Adults by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/535,183 →

Methods for Treating Persistent or Chronic Immune Thrombocytopenia in Children, Adolescents and Adults by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/524,530 →

Methods for Treating Persistent or Chronic Immune Thrombocytopenia in Children, Adolescents and Adults by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 18/756,019 →

Publication: US 2025/0108054

Treatment of Chronic Spontaneous Urticaria by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/652,999 →

Application: 63/593,171 →

Crystalline Form of Tolebrutinib and Preparation Method Thereof

Application: 18/676,250 →

Publication: US 2024/0391915

Crystal Form of Tolebrutinib, Preparation Method Therefor and Use Thereof

Application: 18/568,484 →

Publication: US 2025/0034130

Treatment of Moderate-to-Severe Asthma by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Application: 63/637,741 →

Application: 63/606,952 →

Methods of Making Tolebrutinib

Application: 63/564,100 →

Methods of Making Tolebrutinib

Application: 63/561,794 →

Methods of Making Tolebrutinib

Application: 19/071,185 →

Publication: US 2025/0282777

Methods of Making Modified BTK Inhibitors

Application: 18/875,830 →

Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)

Patent: 11,969,418 →

Application: 17/151,954 →

Publication: US 2021/0244720

Tyrosine Kinase Inhibitors

Patent: 8,962,831 →

Application: 14/117,933 →

Publication: US 2014/0094459

Pyrazolopyrimidine Compounds as Kinase Inhibitors

Patent: 8,940,744 →

Application: 14/464,602 →

Publication: US 2014/0364410

SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS

Patent: 9,266,895 →

Application: 14/374,788 →

Publication: US 2015/0094295

SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS

Patent: 11,040,980 →

Application: 16/708,340 →

Publication: US 2020/0190092

SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS

Patent: 10,533,013 →

Application: 15/978,041 →

Publication: US 2018/0327413

SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS

Patent: 9,994,576 →

Application: 14/997,330 →

Publication: US 2016/0251358

SUBSTITUTED PYRROLO[2,3-b]PYRAZINES AS JAK3 INHIBITORS

Patent: 9,676,778 →

Application: 14/443,705 →

Publication: US 2015/0291600

Treatment of Pemphigus

Patent: 10,946,008 →

Application: 16/593,352 →

Publication: US 2020/0101059

Treatment of Pemphigus

Patent: 10,485,797 →

Application: 15/537,294 →

Publication: US 2018/0050027

Heterocycle Comprising Tyrosine Kinase Inhibitors

Patent: 11,155,544 →

Application: 16/523,979 →

Publication: US 2019/0345159

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

Patent: 12,336,999 →

Application: 18/526,225 →

Publication: US 2024/0207275

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Patent: 11,872,229 →

Application: 17/082,747 →

Publication: US 2021/0113567

Patent: 12,178,818 →

Application: 17/946,585 →

Publication: US 2023/0124267

Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxyphenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Patent: 11,708,370 →

Application: 17/125,384 →

Publication: US 2021/0198264

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxyphenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Patent: 12,281,120 →

Application: 18/306,649 →

Publication: US 2024/0190882

CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXYPHENYL)-1H-PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE

Patent: 11,667,641 →

Application: 17/143,355 →

Publication: US 2021/0206772

Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Patent: 11,583,533 →

Application: 17/143,384 →

Publication: US 2021/0205313

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- Enenitrile

Patent: 12,410,176 →

Application: 18/482,278 →

Publication: US 2024/0182484

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

Patent: 11,814,390 →

Application: 17/154,452 →

Publication: US 2021/0221818

Immunoproteasome Inhibitors

Patent: 11,154,563 →

Application: 16/478,788 →

Publication: US 2019/0336515

Immunoproteasome Inhibitors

Patent: 12,024,531 →

Application: 16/764,199 →

Publication: US 2023/0133165

Immunoproteasome Inhibitors

Patent: 12,312,370 →

Application: 18/380,962 →

Publication: US 2024/0199655

Immunoproteasome Inhibitors

Patent: 11,827,656 →

Application: 17/527,514 →

Publication: US 2022/0073538

Immunoproteasome Inhibitors

Patent: 11,225,493 →

Application: 16/764,136 →

Publication: US 2020/0277312

Benzimidazole Derivatives as Itk Inhibitors

Patent: 9,573,958 →

Application: 14/424,480 →

Publication: US 2015/0225412

Quinolone Derivatives as Fibroblast Growth Factor Inhibitors

Patent: 9,630,963 →

Application: 14/934,885 →

Publication: US 2016/0130268

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Patent: 12,162,882 →

Application: 18/217,002 →

Publication: US 2024/0092777

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Patent: 11,078,199 →

Application: 16/383,237 →

Publication: US 2019/0233418

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Patent: 10,294,223 →

Application: 15/806,525 →

Publication: US 2018/0065960

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Patent: 9,567,334 →

Application: 15/077,442 →

Publication: US 2016/0200725

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Patent: 9,815,834 →

Application: 15/022,869 →

Publication: US 2016/0229849

Quinolone Derivatives as Fgfr Inhibitors

Patent: 10,538,517 →

Application: 15/575,448 →

Publication: US 2018/0155340

Processes for Preparing an Fgfr Inhibitor

Patent: 12,281,110 →

Application: 17/155,726 →

Publication: US 2021/0147417

Processes for Preparing an Fgfr Inhibitor

Patent: 10,899,760 →

Application: 16/745,418 →

Publication: US 2020/0148680

Tyrosine Kinase Inhibitors

Patent: 8,962,635 →

Application: 14/341,421 →

Publication: US 2014/0336382

Tyrosine Kinase Inhibitors

Patent: 9,090,621 →

Application: 14/255,842 →

Publication: US 2014/0309223

Tyrosine Kinase Inhibitors

Patent: 8,946,241 →

Application: 14/185,687 →

Publication: US 2014/0303190

Tyrosine Kinase Inhibitors

Patent: 8,759,358 →

Application: 13/929,179 →

Tyrosine Kinase Inhibitors

Patent: 8,673,925 →

Application: 13/929,004 →

Tyrosine Kinase Inhibitors

Patent: 8,957,080 →

Application: 13/859,569 →

Publication: US 2014/0303161

Crystalline Form of Tolebrutinib

Patent: 12,049,463 →

Application: 17/818,846 →

Publication: US 2022/0389011

Salts and Solid Form of a Btk Inhibitor

Patent: 10,092,569 →

Application: 15/120,293 →

Publication: US 2017/0065591

Salts and Solid Form of a Btk Inhibitor

Patent: 10,456,403 →

Application: 16/116,425 →

Publication: US 2019/0076435

Salts and Solid Form of a Btk Inhibitor

Patent: 10,828,307 →

Application: 16/596,611 →

Publication: US 2020/0038405

Salts and Solid Form of a Btk Inhibitor

Patent: 11,369,613 →

Application: 17/063,061 →

Publication: US 2021/0015821

Tyrosine Kinase Inhibitors

PCT: PCT/US2016/035588 ↗

Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (Rms)

PCT: PCT/US2021/013883 ↗

4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2HIMIDAZO[4,5-C]Pyridin-2-One Derivatives and Salts Thereof

PCT: PCT/US2021/064800 ↗

Tyrosine Kinase Inhibitors

PCT: PCT/US2012/038092 ↗

Formulations Containing Reversible Covalent Compounds

PCT: PCT/US2013/045266 ↗

Pyrazolopyrimidine Compounds as Kinase Inhibitors

PCT: PCT/US2013/058614 ↗

Azaindole Derivatives as JAK3 Inhibitors

PCT: PCT/US2013/070834 ↗

Salts and Solid Form of a Btk Inhibitor

PCT: PCT/US2015/016963 ↗

Compositions for Ileo-Jejunal Drug Delivery

PCT: PCT/US2015/000515 ↗

Treatment of Pemphigus

PCT: PCT/US2015/066868 ↗

Site Specific Dosing of a Btk Inhibitor

PCT: PCT/US2015/000303 ↗

Tyrosine Kinase Inhibitors

PCT: PCT/US2016/039070 ↗

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2017/040075 ↗

PCT: PCT/US2020/054809 ↗

PCT: PCT/US2020/055410 ↗

Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2020/065689 ↗

Treatment of Membranous Nephropathy, IGG4-Related Disease, and Antiphospholipid Syndrome Using Btk Inhibitor 2-[(3R)-3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2021/012211 ↗

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

PCT: PCT/US2021/012515 ↗

Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

PCT: PCT/US2021/012507 ↗

Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2021/014371 ↗

Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using Btk Inhibitors

PCT: PCT/US2021/028381 ↗

Methods for Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds

PCT: PCT/US2022/024806 ↗

Immunoproteasome Inhibitors

PCT: PCT/US2018/013823 ↗

Immunoproteasome Inhibitors

PCT: PCT/US2018/061132 ↗

Immunoproteasome Inhibitors

PCT: PCT/US2018/061140 ↗

Benzimidazole Derivatives as Kinase Inhibitors

PCT: PCT/US2013/056877 ↗

Quinolone Derivatives as Fibroblast Growth Factor Inhibitors

PCT: PCT/US2014/037173 ↗

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

PCT: PCT/US2015/014460 ↗

Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors

PCT: PCT/US2016/033065 ↗

Processes for Preparing an Fgfr Inhibitor

PCT: PCT/US2016/046304 ↗

Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and Derivatives Thereof

PCT: PCT/US2022/053479 ↗

Cyclic Boronic Esters and Their Uses

PCT: PCT/US2023/026427 ↗

Solid Forms of 2-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D]Pyrimidn-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2023/025124 ↗

Therapeutic Tyrosine Kinase Inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Disease (Mogad)

PCT: PCT/US2023/022042 ↗

Methods of Making Tolebrutinib

PCT: PCT/US2023/025170 ↗

Methods of Making Modified Btk Inhibitors

PCT: PCT/US2023/025808 ↗

PCT: PCT/US2024/040259 ↗

Drug Formulations of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One

PCT: PCT/US2023/084784 ↗

PCT: PCT/US2023/078211 ↗

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis and Myasthenia Gravis

PCT: PCT/US2023/026526 ↗

Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis

PCT: PCT/US2023/034655 ↗

PCT: PCT/US2023/083090 ↗

Treatment of Itch Associated with Atopic Dermatitis and/or Prurigo Nodularis Using Btk Inhibitor 2-[(3R)-3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2024/052716 ↗

Methods of Diagnosing and Treating Multiple Sclerosis

PCT: PCT/US2024/013658 ↗

Methods for Treating Persistent or Chronic Immune Thrombocytopenia in Children, Adolescents and Adults by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxyphenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2024/035719 ↗

Treatment of Chronic Spontaneous Urticaria by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4- D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile

PCT: PCT/US2024/052717 ↗

PCT: PCT/US2024/058667 ↗

Methods of Making Tolebrutinib

PCT: PCT/US2025/018520 ↗

Related Assignments (23)

Other recorded transfers of the patents in this record — the chain of ownership.

Assignment of Assignor's Interest Oct 11, 2011

From: GOLDSTEIN, DAVID; BRAMELD, KENNETH

To: PRINCIPIA BIOPHARMA, INC.

Reel/Frame 027043/0074 →

Assignment of Assignor's Interest Nov 12, 2014

From: GOLDSTEIN, DAVID MICHAEL; BRAMELD, KENNETH ALBERT